A REVIEW OF RECENT ADVANCES IN THE DEVICES FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- Annapu Reddy Harshith B. Pharmacy, Iv Year, Ratnam Institute Of Pharmacy, Pidathapolur, (V & P), Muthukur (M), Spsr Nellore District-524 346, Andhra Pradhesh.
-
Yeddu Sribharathi
Assistant Professor, Department Of Pharmacy Practice, Ratnam Institute Of Pharmacy, Pidathapolur, (V & P), Muthukur (M), Spsr Nellore District-524 346, Andhra Pradesh.
sribharathiyeddu@gmail.com
- Afroz Patan Professor And HOD, Department Of Pharmacy Practice, Ratnam Institute Of Pharmacy, Pidathapolur (V & P), Muthukur (M), Spsr Nellore District-524 346, Andhra Pradesh.
- Yadala Prapurna Chandra Principle And Professor, Department Of Pharmacology, Ratnam Institute Of Pharmacy, Pidathapolur, (V & P), Muthukur (M), Spsr Nellore District-524 346, Andhra Pradesh.
Abstract
A frequent respiratory condition with a high morbidity and mortality rate is chronic obstructive pulmonary disease (COPD). Many people do not receive a diagnosis until the disease has progressed clinically, and COPD is underdiagnosed despite its prevalence. Current studies on early COPD modifications aim to identify people for early intervention, enhance diagnostic, and uncover new targets for treatment. Over the past 20 years, there has been a significant increase in the number of COPD therapies available due to this focus, new oral and inhaled drugs, and innovative procedures. The gradual lung dysfunction known as chronic obstructive pulmonary disease (COPD) is mostly brought on by smoking cigarettes and breathing in harmful particles. the persistent exposure to disastrous chemicals might lead to aberrant inflammatory reactions, permanent damages to the respiratory system, and irreversible pathological alterations. Mitochondrial and epigenetic changes are increasingly recognized as playing a role in (COPD) development, alongside genetics and aging. these alterations include mitochondrial damage, excess production of reactive oxygen species, abnormal the cell's self-cleaning process, and altered and (programmed cell death). Epigenetic modifications like DNA methylation, histone.
Keywords:
COPD, pulmonary rehabilitation, digital health, exacerbations, inhaler technique, machine learning, and patient involvement
Downloads
Download data is not yet available.
References
1. Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023.
2. World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva: WHO; 2021.
3. World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva: WHO; 2021.
4. Yawn BP, Mintz ML, Doherty DE. GOLD in practice: chronic obstructive pulmonary disease treatment and management in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289–299.
5. Singh D, Agustí A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
6. Vamsi V, SomaSekhar K, Sandeep R, Meghana B, Sharmila S. Case report on pulmonary mucormycosis. Int J Health Care Biol Sci. 2023;7:7–9.
7. Ho T, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective. Breathe (Sheff). 2019;15(1):24–35.
8. Singh D, Agustí A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
9. Faruque MO, Boezen HM, Kromhout H, et al. Airborne occupational exposures and the risk of developing respiratory symptoms and airway obstruction in the Lifelines Cohort Study. Thorax. 2021;76(8):790–797.
10. Venkatesh P. Review on tuberculosis. UPI J Pharm Med Health Sci. 2022;15–18.
11. Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration. 2012;84(2):89–97.
12. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–459.
13. Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, Stolk J, Hiemstra PS. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018;73(6):565–574.
14. Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, Stolk J, Hiemstra PS. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018;73(6):565–574.
15. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;182:693–718.
16. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;385:899–909.
17. Vamsi V, SomaSekhar K, Sandeep R, Meghana B, Sharmila S. Case report on pulmonary mucormycosis. Int J Health Care Biol Sci. 2023;7:7–9.
18. Camp PG, Ramirez-Venegas A, Sansores RH, Alva LF, McDougall JE, Sin DD, et al. COPD phenotypes in biomass smoke- versus tobacco smoke-exposed Mexican women. Eur Respir J. 2014;43:725–734.
19. Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, Stolk J, Hiemstra PS. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018;73(6):565–574.
20. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care. 2005;50(9):1139–1150.
21. Susmitha N, Venkatesh P. Review on infectious diseases. Int J Indigenous Herbs Drugs. 2022;18–21.
22. van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14(5):1034–1037.
23. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127(1):335–371. (Note: Replaced narrative statement with appropriate guideline citation format.)
24. Narasimha GL, Dornadula GR. A case report on pleural effusion induced by pulmonary tuberculosis reactivation. Int J Sci Res. 2019;8(8).
25. Borel JC, Pelletier J, Taleux N, Briault A, Arnol N, Pison C, et al. Parameters recorded by software of non-invasive ventilators predict COPD exacerbation: a proof-of-concept study. Thorax. 2015;70:284–285.
26. Rubio N, Parker RA, Drost EM, Pinnock H, Weir CJ, Hanley J, et al. Home monitoring of breathing rate in people with chronic obstructive pulmonary disease: observational study of feasibility, acceptability, and change after exacerbation. Int J Chron Obstruct Pulmon Dis. 2017;12:1221–1231.
27. Walker PP, Pompilio PP, Zanaboni P, Bergmo TS, Prikk K, Malinovschi A, et al. Telemonitoring in chronic obstructive pulmonary disease (CHROMED): a randomized clinical trial. Am J Respir Crit Care Med. 2018;198:620–628.
28. Gunturu LN, Pamayyagari K, Dornadula GR. A case report on herpes zoster eruption associated with chronic obstructive pulmonary disease. Int J Ther Appl. 2020;37.
29. Gonem S, Janssens W, Das N, Topalovic M. Applications of artificial intelligence and machine learning in respiratory medicine. Thorax. 2020;75:695–701.
30. Grzesiak E, Bent B, McClain MT, Woods CW, Tsalik EL, Nicholson BP, et al. Assessment of the feasibility of using noninvasive wearable biometric monitoring sensors to detect influenza and the common cold before symptom onset. JAMA Netw Open. 2021;4:e2128534.
31. Hörmann C, Baum M, Putensen C, Mutz NJ, Benzer H. Biphasic positive airway pressure (BIPAP)—a new mode of ventilatory support. Eur J Anaesthesiol. 1994;11(1):37–42.
32. Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax. 2016;71(Suppl 2):ii1–ii35.
33. Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981.
34. Martinez CH, Mannino DM, Jaimes FA, et al. Undiagnosed obstructive lung disease in the United States: associated factors and long-term mortality. Ann Am Thorac Soc. 2015;12:1788–1795.
35. Criner GJ, et al. Advances in the diagnosis and management of chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2220–2236.
36. Singh D, Agustí A, et al. COPD diagnosis and monitoring: new tools and techniques. Eur Respir J. 2023;61(2):2201234.
37. Topalovic M, et al. Artificial intelligence and machine learning in spirometry interpretation. Am J Respir Crit Care Med. 2021;204(11):1261–1270.
38. Kainu A, et al. Validation of portable and home spirometry for COPD diagnosis and monitoring. Chest. 2020;158(6):2434–2445.
39. Bohadana A, et al. Impulse oscillometry in chronic obstructive pulmonary disease: applications and clinical relevance. Respir Med. 2021;186:106524.
40. Mets OM, et al. Quantitative CT and AI-driven radiomics in COPD: current status and future perspectives. Thorax. 2022;77(7):639–649.
41. Dragonieri S, et al. Electronic nose technology and exhaled breath analysis in COPD and asthma diagnosis. Front Med (Lausanne). 2023;10:1168749.
42. Rabbani M, et al. Smart wearable systems for respiratory disease detection using breath biomarkers. Sensors (Basel). 2024;24(4):1198.
43. Pachauri N, et al. Exhaled breath condensate analysis: current techniques and diagnostic applications in COPD. J Breath Res. 2022;16(3):036007.
44. Cowie MR, et al. Remote patient monitoring in chronic respiratory disease: recent advances and challenges. npj Digit Med. 2023;6:77.
45. Criner GJ, Han MK. COPD care in the 21st century: a public health priority. Respir Med. 2018;145:1–3.
46. Lavorini F, Fontana GA, Usmani OS. New inhaler devices—the good, the bad and the ugly. Respir Med. 2014;108(6):775–783.
47. Criner GJ, Han MK. COPD care in the 21st century: a public health priority. Respir Med. 2018;145:1–3.
48. Roca O, Hernández G, Díaz-Lobato S, Carratalá JM, Gutiérrez A. Current evidence for the effectiveness of heated and humidified high-flow nasal cannula supportive therapy in adult patients with respiratory failure. Crit Care. 2016;20(1):109.
49. Chatburn RL. High-flow nasal cannula oxygen therapy for adult patients. Respir Care. 2010;55(4):408–413.
50. Kocks JWH, Chrystyn H, van der Palen J, Thomas M, Yates LM, Landis SH, et al. Systematic review of the effectiveness of critical errors in inhalation devices on health outcomes in COPD and asthma. NPJ Prim Care Respir Med. 2018;28(1):43.
2. World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva: WHO; 2021.
3. World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva: WHO; 2021.
4. Yawn BP, Mintz ML, Doherty DE. GOLD in practice: chronic obstructive pulmonary disease treatment and management in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289–299.
5. Singh D, Agustí A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
6. Vamsi V, SomaSekhar K, Sandeep R, Meghana B, Sharmila S. Case report on pulmonary mucormycosis. Int J Health Care Biol Sci. 2023;7:7–9.
7. Ho T, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective. Breathe (Sheff). 2019;15(1):24–35.
8. Singh D, Agustí A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
9. Faruque MO, Boezen HM, Kromhout H, et al. Airborne occupational exposures and the risk of developing respiratory symptoms and airway obstruction in the Lifelines Cohort Study. Thorax. 2021;76(8):790–797.
10. Venkatesh P. Review on tuberculosis. UPI J Pharm Med Health Sci. 2022;15–18.
11. Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration. 2012;84(2):89–97.
12. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–459.
13. Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, Stolk J, Hiemstra PS. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018;73(6):565–574.
14. Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, Stolk J, Hiemstra PS. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018;73(6):565–574.
15. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;182:693–718.
16. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;385:899–909.
17. Vamsi V, SomaSekhar K, Sandeep R, Meghana B, Sharmila S. Case report on pulmonary mucormycosis. Int J Health Care Biol Sci. 2023;7:7–9.
18. Camp PG, Ramirez-Venegas A, Sansores RH, Alva LF, McDougall JE, Sin DD, et al. COPD phenotypes in biomass smoke- versus tobacco smoke-exposed Mexican women. Eur Respir J. 2014;43:725–734.
19. Broekman W, Khedoe PPSJ, Schepers K, Roelofs H, Stolk J, Hiemstra PS. Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax. 2018;73(6):565–574.
20. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care. 2005;50(9):1139–1150.
21. Susmitha N, Venkatesh P. Review on infectious diseases. Int J Indigenous Herbs Drugs. 2022;18–21.
22. van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14(5):1034–1037.
23. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127(1):335–371. (Note: Replaced narrative statement with appropriate guideline citation format.)
24. Narasimha GL, Dornadula GR. A case report on pleural effusion induced by pulmonary tuberculosis reactivation. Int J Sci Res. 2019;8(8).
25. Borel JC, Pelletier J, Taleux N, Briault A, Arnol N, Pison C, et al. Parameters recorded by software of non-invasive ventilators predict COPD exacerbation: a proof-of-concept study. Thorax. 2015;70:284–285.
26. Rubio N, Parker RA, Drost EM, Pinnock H, Weir CJ, Hanley J, et al. Home monitoring of breathing rate in people with chronic obstructive pulmonary disease: observational study of feasibility, acceptability, and change after exacerbation. Int J Chron Obstruct Pulmon Dis. 2017;12:1221–1231.
27. Walker PP, Pompilio PP, Zanaboni P, Bergmo TS, Prikk K, Malinovschi A, et al. Telemonitoring in chronic obstructive pulmonary disease (CHROMED): a randomized clinical trial. Am J Respir Crit Care Med. 2018;198:620–628.
28. Gunturu LN, Pamayyagari K, Dornadula GR. A case report on herpes zoster eruption associated with chronic obstructive pulmonary disease. Int J Ther Appl. 2020;37.
29. Gonem S, Janssens W, Das N, Topalovic M. Applications of artificial intelligence and machine learning in respiratory medicine. Thorax. 2020;75:695–701.
30. Grzesiak E, Bent B, McClain MT, Woods CW, Tsalik EL, Nicholson BP, et al. Assessment of the feasibility of using noninvasive wearable biometric monitoring sensors to detect influenza and the common cold before symptom onset. JAMA Netw Open. 2021;4:e2128534.
31. Hörmann C, Baum M, Putensen C, Mutz NJ, Benzer H. Biphasic positive airway pressure (BIPAP)—a new mode of ventilatory support. Eur J Anaesthesiol. 1994;11(1):37–42.
32. Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax. 2016;71(Suppl 2):ii1–ii35.
33. Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981.
34. Martinez CH, Mannino DM, Jaimes FA, et al. Undiagnosed obstructive lung disease in the United States: associated factors and long-term mortality. Ann Am Thorac Soc. 2015;12:1788–1795.
35. Criner GJ, et al. Advances in the diagnosis and management of chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2220–2236.
36. Singh D, Agustí A, et al. COPD diagnosis and monitoring: new tools and techniques. Eur Respir J. 2023;61(2):2201234.
37. Topalovic M, et al. Artificial intelligence and machine learning in spirometry interpretation. Am J Respir Crit Care Med. 2021;204(11):1261–1270.
38. Kainu A, et al. Validation of portable and home spirometry for COPD diagnosis and monitoring. Chest. 2020;158(6):2434–2445.
39. Bohadana A, et al. Impulse oscillometry in chronic obstructive pulmonary disease: applications and clinical relevance. Respir Med. 2021;186:106524.
40. Mets OM, et al. Quantitative CT and AI-driven radiomics in COPD: current status and future perspectives. Thorax. 2022;77(7):639–649.
41. Dragonieri S, et al. Electronic nose technology and exhaled breath analysis in COPD and asthma diagnosis. Front Med (Lausanne). 2023;10:1168749.
42. Rabbani M, et al. Smart wearable systems for respiratory disease detection using breath biomarkers. Sensors (Basel). 2024;24(4):1198.
43. Pachauri N, et al. Exhaled breath condensate analysis: current techniques and diagnostic applications in COPD. J Breath Res. 2022;16(3):036007.
44. Cowie MR, et al. Remote patient monitoring in chronic respiratory disease: recent advances and challenges. npj Digit Med. 2023;6:77.
45. Criner GJ, Han MK. COPD care in the 21st century: a public health priority. Respir Med. 2018;145:1–3.
46. Lavorini F, Fontana GA, Usmani OS. New inhaler devices—the good, the bad and the ugly. Respir Med. 2014;108(6):775–783.
47. Criner GJ, Han MK. COPD care in the 21st century: a public health priority. Respir Med. 2018;145:1–3.
48. Roca O, Hernández G, Díaz-Lobato S, Carratalá JM, Gutiérrez A. Current evidence for the effectiveness of heated and humidified high-flow nasal cannula supportive therapy in adult patients with respiratory failure. Crit Care. 2016;20(1):109.
49. Chatburn RL. High-flow nasal cannula oxygen therapy for adult patients. Respir Care. 2010;55(4):408–413.
50. Kocks JWH, Chrystyn H, van der Palen J, Thomas M, Yates LM, Landis SH, et al. Systematic review of the effectiveness of critical errors in inhalation devices on health outcomes in COPD and asthma. NPJ Prim Care Respir Med. 2018;28(1):43.
Statistics
83 Views | 67 Downloads
How to Cite
Annapu, R. H., Yeddu, S., Afroz, P., & Yadala, P. C. (2026). A REVIEW OF RECENT ADVANCES IN THE DEVICES FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Asian Journal of Hospital Pharmacy, 6(1), 1-8. https://doi.org/10.38022/ajhp.v6i1.125
Issue
Section
Review Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
.